Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Pluristem planning phase III study of PLX-PAD cells for muscle recovery after arthroplasty

Sep. 27, 2017

Medivir reports promising topline data on MIV-711 in knee osteoarthritis

Sep. 27, 2017

Janssen Biotech receives complete response letter for sirukumab BLA

Sep. 26, 2017

ImmuPharma offers update on Lupuzor program

Sep. 26, 2017

NIH grant to support development of Cel-Sci's rheumatoid arthritis vaccine

Sep. 20, 2017

Boehringer Ingelheim receives positive opinion for adalimumab biosimilar Cyltezo

Sep. 18, 2017

Phase III trial of upadacitinib in rheumatoid arthritis meets all endpoints

Sep. 12, 2017

Daiichi Sankyo and Sanford Burnham Prebys begin clinical trial of DS-1211

Sep. 7, 2017

Promising RORgammaT inhibitors discovered at Merck & Co.

Sep. 5, 2017

EMD Serono details discovery of BTK inhibitor now in clinical development

Sep. 4, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...